Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
48 hedge funds and large institutions have $24.5M invested in Generation Bio in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
17% more funds holding
Funds holding: 41 → 48 (+7)
5.07% more ownership
Funds ownership: 58.93% → 64% (+5.1%)
1% more capital invested
Capital invested by funds: $24.2M → $24.5M (+$283K)
33% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.75M |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$555K |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
+$247K |
| 4 |
Two Sigma Investments
New York
|
+$215K |
| 5 |
DAM
Deltec Asset Management
New York
|
+$184K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.07M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.19M |
| 3 |
CF
Cantor Fitzgerald
New York
|
-$606K |
| 4 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$539K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$442K |
GBIO Hedge Fund Activity: Q4 2025 in Review
48 of the 8,243 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q4 2025, worth a combined $24.5M — up 1.2% from $24.2M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new GBIO positions and 4 closed out — a net gain of 7 holders — while 10 added to existing stakes and 15 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $1.75M. The largest seller was T. Rowe Price Associates, cutting an estimated $2.07M.
- 48 institutional investors held Generation Bio (GBIO) as of Q4 2025, up from 41 in Q3 2025.
- Funds reported $24.5M of Generation Bio stock for Q4 2025, up 1.2% quarter-over-quarter.
- 11 funds opened new Generation Bio positions in Q4 2025 and 4 closed out, a net change of +7 holders.
- The largest Generation Bio buyer in Q4 2025 was Opaleye Management, an estimated $1.75M added.
- The largest Generation Bio seller in Q4 2025 was T. Rowe Price Associates, an estimated $2.07M sold.
Based on aggregated 13F filings for Q4 2025.